Long-term safety and efficacy of efgartigimod in generalized myasthenia gravis during the ADAPT+ study
Abstract
Background: Efgartigimod is a human immunoglobulin G1 (IgG1) antibody Fc-fragment that reduces total and pathogenic IgG autoantibody levels through neonatal Fc receptor blockade. ADAPT was a 26-week, global, multicenter, randomized, placebo-controlled, phase 3 trial evaluating efgartigimod in participants with generalized myasthenia gravis. Participants who completed ADAPT could enroll in the ADAPT+ open-label extension study. Objective: To evaluate long-term safety and efficacy of efgartigimod in participants with generalized myasthenia gravis. Methods: Efgartigimod (10 mg/kg; intravenous) was administered in cycles of 4 once-weekly infusions, with subsequent cycles initiated based on clinical evaluation. Efficacy was assessed using Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis scores. Results: Of 167 participants from ADAPT, 151 (90%) entered ADAPT+, and 145 received ≥1 cycle as of January 2022. With 217.5 participant-years of follow-up (mean duration per participant: 548 days), the most common adverse events (mostly mild or moderate) were headache (25%), COVID-19 infection (15%), nasopharyngitis (14%), and diarrhea (10%). These adverse events did not increase in frequency with subsequent cycles. Acetylcholine receptor antibody positive (AChR-Ab+) participants (ADAPT/ADAPT+ primary endpoint population) with ≥1 year of follow-up across ADAPT/ADAPT+ (n=95) received a median (range) 5.0 (0.4-7.6) cycles per year. AChR-Ab+ participants (n=111) demonstrated consistent improvements (mean change [standard error], Week 3 of cycle 1) in Myasthenia Gravis Activities of Daily Living (–5.0 [0.33]; repeated ≤14 cycles) and Quantitative Myasthenia Gravis (–4.7 [0.41]; repeated ≤7 cycles) scores. Conclusion: These ADAPT+ analyses suggest long-term efgartigimod treatment is well tolerated and results in consistent and repeatable reductions in clinical outcomes (Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis scores) in participants with generalized myasthenia gravis.